APPROACH
Distributor Search & Qualification
Know which distributors deserve first contact.
For one defined MedTech or IVD product in one selected country, GHMAP maps the credible distributor landscape, assesses product, channel, conflict and applicable local-role fit, and shows which candidates merit outreach, which require verification and which should be excluded.$7,500 · ONE PRODUCT · ONE COUNTRY · 20 BUSINESS DAYS
Evidence-based · Product-specific · Human-reviewed · No numerical scoring. Research only. Direct distributor contact is available separately. Delivery begins after complete intake, written scope acceptance and requirement lock.
Management decision
Approach. Verify. Exclude. Hold.
The output is a defensible outreach decision — not a claim that GHMAP found the best distributor, a verified partner, or a guaranteed qualified distributor.
VERIFY
EXCLUDE
HOLD
Why lists are not enough
Discovery tools find names. They do not finish the decision.
Google, LinkedIn, AI tools, databases and trade-show directories can surface candidates. They do not, by themselves, establish product fit, channel fit, competitor conflict, applicable importer or regulatory role, relevant technical or service capability, or whether a candidate deserves management outreach.
Search process
From requirement lock to management decision
Research limits, not guaranteed candidate counts. GHMAP may recommend fewer than 3–5 where the evidence does not support a larger first-wave list.
- Product + Country
- Distributor Requirement Lock
- Multi-path / Local-language Discovery
- 10–15 Screened Distributors
- 10 Detailed Public-evidence Assessments
- 3–5 Recommended for Outreach
- Management Decision
Sample deliverable
See an anonymized example
Five screened distributors in Turkey, assessed against the same checklist, with one candidate recommended. Company names are withheld and every figure is illustrative.
Turkey · Distributor Search sample
The shortlist checklist, vetting checklist, risk notes and a recommended next step — the same structure your own report would follow.
Qualification framework
Product- and country-specific criteria
Criteria change according to product and country. Not every criterion applies to every project.
Core
- Legal and operating identity
- Target-country presence
- Product/category fit
- Clinical-specialty fit
- Customer/channel fit
- Existing portfolio
- Competitor conflict
- Geographic fit
Where applicable
- Importer/distributor role
- Authorized Representative / local regulatory role
- Tender / institutional procurement
- Installation
- Maintenance
- Applications support
- Training
- Warehousing
- Consumable logistics
Candidate classifications
Four classifications. No aggregate score.
One material conflict or unresolved regulatory role may matter more than multiple weaker positive signals.
RECOMMENDED FOR OUTREACH
Public evidence supports first-wave contact under the locked product and country requirement.
CONDITIONAL — VERIFICATION REQUIRED
Relevant signals exist, but a material role, identity, conflict, or capability question must be resolved before outreach priority can rise.
NOT RECOMMENDED
Product-specific conflict, weak fit, or unresolved adverse evidence does not support outreach for this project.
INSUFFICIENT EVIDENCE
Public evidence is too thin to recommend, exclude, or prioritize responsibly.
Customer deliverables
What you receive
Internal working notes and the internal Evidence Ledger are not customer deliverables.
01
Executive Distributor Decision Report
Management-facing shortlist, classifications, priorities, material conflicts, unknowns, and recommended next verification actions.
02
Customer Evidence & Candidate Workbook
Candidate universe, detailed assessments, source references, and decision support in a structured workbook.
03
45-Minute Decision Review
Review the shortlist, evidence basis, major unknowns, and recommended verification sequence with GHMAP.
04
Correction & Clarification Window
One consolidated correction and clarification submission for factual fixes, broken links, identity labels, and relevant pre-cutoff public evidence.
Methodology / trust
Evidence discipline before outreach
GHMAP supports the outreach decision. GHMAP does not certify legal eligibility, financial strength, hospital access, distributor interest, or future commercial performance.
Official sources first
Regulators, procurement systems, government records, and manufacturer evidence are prioritized before company claims.
Product-specific criteria
Fit is judged against the locked product, channels, and country role map — not a generic distributor directory.
Company claims labeled
Distributor website and company-reported statements are labeled as company-reported unless corroborated.
Missing evidence disclosed
Not verified is stated openly. Absence of public evidence is not automatically treated as an adverse finding.
Conflicts preserved
Direct substitution, adjacent overlap, complementary portfolios, and unknowns stay visible for management judgment.
No numerical score
Candidate decisions use written evidence, explicit unknowns, and management priority — not aggregate gauges.
Human QA
Material conclusions receive human review inside the sample-production environment. This is not independent external assurance.
Publicly verifiedCompany-reportedDirect-contact evidenceNot verifiedFormal due diligence required
Global country-specific methodology
One decision standard. Country-specific evidence paths.
Every project begins with a Country Role Map.
01
TÜRKİYE
- ÜTS / TİTCK
- MERSİS / Trade Registry
- EKAP
- Applicable import-control context
- Direct confirmation for unpublished capability and current interest
02
GERMANY
- MDR / IVDR economic-operator structure
- EUDAMED where applicable
- Commercial registries
- Procurement evidence
- Direct confirmation for territory, service, portfolio and willingness
03
UNITED KINGDOM
- MHRA
- UK Responsible Person
- Companies House
- NHS / Find a Tender
- Great Britain vs Northern Ireland distinction
- Direct confirmation for commercial/service capability
04
SAUDI ARABIA
- SFDA
- NUPCO
- Etimad
- Direct confirmation for regulatory intent, service competence, logistics and interest
An official establishment or economic-operator record does not prove product appointment, commercial capacity, hospital access or current interest.
Optional add-on
CONTACT QUALIFICATION & INTEREST CONFIRMATION
Research identifies who deserves outreach. Contact Qualification identifies who responds, what they report and who confirms interest. +$3,500. 20-business-day active outreach window.
- Approved GHMAP shortlist
- Up to five candidates
- Initial contact
- Up to two follow-ups
- Responsible-person confirmation
- High-level product/category/channel clarification
- Applicable regulatory/import clarification
- Relevant service clarification
- Conflict clarification
- Interest classification
- Response / non-response tracking
- Permission-based introduction where available
- Updated workbook
- Contact Qualification Addendum
NO RESPONSE does not mean Not Qualified, Not Interested or Weak. GHMAP guarantees the agreed outreach process. GHMAP does not guarantee response, interest, meeting, appointment, exclusivity, registration, tender success or sales.
Pricing
Fixed scope. Request-first payment.
Base
Evidence-Based Distributor Search
$7,500
One product · One country · 20 business days
Optional
Contact Qualification & Interest Confirmation
+$3,500
20-business-day active outreach window
Combined: $11,000 when both stages are contracted at project start.
Who it is for
Built for a defined product and country decision
Best fit
- Defined MedTech / IVD / healthcare-technology product
- Selected target country
- Commercially ready or near-ready
- Needs a distributor, importer, or product-relevant service partner
- Product, channel, regulatory, and conflict fit matter
- Management needs a defensible shortlist before outreach, travel, or launch investment
Not ideal
- Idea-stage product
- No target country
- Generic market exploration
- Hundreds of unassessed leads
- Legal / financial due diligence
- Guaranteed immediate sales or appointment
Exclusions
Intelligence first. Appointment is separate.
Not included in the base research package:
- Detailed distributor interviews
- Manufacturer–distributor meetings
- Site visits
- Reference checks
- Legal / ownership / sanctions / credit / financial diligence
- Contract drafting or review
- Negotiation
- Distributor appointment
- Onboarding
- Ongoing sales representation
FAQ
Common questions
What is Distributor Search & Qualification?
An evidence-based research engagement that maps the credible distributor landscape for one defined MedTech or IVD product in one selected country, assesses fit and conflicts, and shows which candidates merit outreach.
Is this the same as the Market Entry Sprint?
No. The Market Entry Sprint is a broader market-entry package. Product-specific Distributor Search & Qualification is a separate request-first service with its own methodology, deliverables, and price.
Do you guarantee 3–5 recommended distributors?
No. 10–15 candidates are screened and 10 assessed in detail. GHMAP normally recommends 3–5 for outreach when the evidence supports that, and may recommend fewer when it does not.
Does GHMAP contact distributors in the base package?
No. The base package is research only. Direct distributor contact is available separately as Contact Qualification & Interest Confirmation.
When does delivery begin?
After complete intake, written scope acceptance, requirement lock, private first payment, and formal Start Notice.
Does an SFDA or similar establishment record mean the candidate is qualified?
No. An official establishment or economic-operator record supports the recorded role. It does not prove product appointment, commercial capacity, hospital access, or current interest.
Can I pay online immediately?
No. Distributor Search is request-first. GHMAP reviews feasibility and locks written scope before private payment instructions are issued.
Distributor Search & Qualification
Know which distributors deserve first contact.
$7,500 · One product · One country · 20 business days. Request-first — GHMAP confirms scope before payment.
No patient data on public forms.